Get the Stockscreener App
13.83
3.06%
0.41
After Hours:
13.95
0.12
+0.87%
Cadrenal Therapeutics Inc stock is traded at $13.83, with a volume of 31,115.
It is up +3.06% in the last 24 hours and up +6.71% over the past month.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
See More
Previous Close:
$13.42
Open:
$13.45
24h Volume:
31,115
Relative Volume:
0.99
Market Cap:
$28.31M
Revenue:
-
Net Income/Loss:
$-4.85M
P/E Ratio:
-44.61
EPS:
-0.31
Net Cash Flow:
$-3.95M
1W Performance:
+1.10%
1M Performance:
+6.71%
6M Performance:
-21.55%
1Y Performance:
+1.32%
1-Day Range:
$13.24
$13.85
1-Week Range:
$13.24
$14.64
52-Week Range:
$8.74
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
13.83 | 27.47M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
CVKD: Acquires Factor XIa Inhibitors - Smartkarma
CVKD: Acquires Factor XIa Inhibitors… - Yahoo Finance
Backtesting results for Cadrenal Therapeutics Inc. trading strategiesMarket Sentiment Report & Free Growth Oriented Trading Recommendations - newser.com
Will a bounce in Cadrenal Therapeutics Inc. offer an exitWeekly Investment Recap & Consistent Return Investment Signals - newser.com
Can Cadrenal Therapeutics Inc. stock beat market expectations this quarterJuly 2025 Momentum & Risk Adjusted Swing Trade Ideas - newser.com
Can Cadrenal Therapeutics Inc. stock sustain institutional interestFed Meeting & Growth Focused Stock Pick Reports - newser.com
Cadrenal Therapeutics Inc Stock Analysis and ForecastVolume Analysis Techniques & Hidden Gems with Outstanding Profit Margins - earlytimes.in
Cadrenal Therapeutics Inc. stock daily chart insightsQuarterly Performance Summary & Consistent Return Investment Signals - newser.com
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - GlobeNewswire
Anticoagulation Therapy Biotech Cadrenal Therapeutics to Showcase Pipeline at Lytham Investor Conference - Stock Titan
Published on: 2025-09-30 10:26:28 - earlytimes.in
Custom watchlist performance reports with Cadrenal Therapeutics Inc.Weekly Trading Summary & AI Optimized Trade Strategies - newser.com
Multi factor analysis applied to Cadrenal Therapeutics Inc.2025 Support & Resistance & Daily Profit Maximizing Trade Tips - newser.com
What analysts say about Cadrenal Therapeutics Inc stockLow Beta Stocks & High Return Trading Ideas - earlytimes.in
Cadrenal therapeutics (CVKD) CEO Pham sells $131,779 in stock By Investing.com - Investing.com South Africa
Cadrenal therapeutics (CVKD) CEO Pham sells $131,779 in stock - Investing.com India
Szot, CFO of Cadrenal, sells $174k in CVKD stock - Investing.com India
Is Cadrenal Therapeutics Inc. stock attractive for income investorsMarket Activity Summary & Expert Verified Stock Movement Alerts - newser.com
Can EFC$D stock test all time highsTrade Signal Summary & Daily Profit Maximizing Tips - newser.com
Cadrenal Therapeutics Elects New Director at Meeting - TipRanks
Should you hold or exit Conduit Pharmaceuticals Inc. Equity Warrant nowNew Guidance & Smart Money Movement Alerts - newser.com
Can Cadrenal Therapeutics Inc. rally from current levels2025 Geopolitical Influence & Low Risk Entry Point Tips - newser.com
Is now a turning point for Cadrenal Therapeutics Inc.Earnings Trend Report & Daily Profit Maximizing Tips - newser.com
How does Apollomics Inc Equity Warrant compare to its peers2025 Risk Factors & Low Volatility Stock Suggestions - خودرو بانک
How to monitor Cadrenal Therapeutics Inc. with trend dashboards2025 Trade Ideas & Weekly Top Performers Watchlists - newser.com
Market Pulse: What is the next catalyst for Cadrenal Therapeutics Inc2025 Trading Volume Trends & Real-Time Sentiment Analysis - خودرو بانک
Resistance Check: Should I average down on MaxCyte Inc stockMarket Activity Summary & Stepwise Entry/Exit Trade Alerts - khodrobank.com
Short Squeeze: Is Cadrenal Therapeutics Inc. a top pick in the sectorLong Setup & AI Powered Market Entry Strategies - خودرو بانک
Energy Moves: Whats the profit margin of EWBCTrade Entry Report & Daily Growth Stock Investment Tips - خودرو بانک
Is it time to cut losses on Cadrenal Therapeutics Inc.Quarterly Market Summary & AI Forecast for Swing Trade Picks - newser.com
Trend analysis for Ideal Power Inc. this week2025 Earnings Impact & Momentum Based Trading Ideas - newser.com
Using Python tools to backtest Cadrenal Therapeutics Inc. strategiesAnalyst Downgrade & Low Drawdown Momentum Ideas - newser.com
Deal Watch: Biogen Acquires Intrathecal Delivery Specialist Alcyone - insights.citeline.com
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):